Process utilities for topical treatment in atopic dermatitis

被引:7
|
作者
Retzler, Jenny [1 ,2 ]
Smith, Adam [1 ]
Reaney, Matthew [3 ]
Rout, Raj [3 ]
Hudson, Richard [3 ]
机构
[1] Univ York, York Hlth Econ Consortium, York, N Yorkshire, England
[2] Univ Huddersfield, Dept Psychol, Huddersfield, W Yorkshire, England
[3] Sanofi Genzyme UK & Ireland, 1 Onslow St, Guildford GU1 4SY, Surrey, England
关键词
Utility elicitation; Time trade-off; Atopic dermatitis; Process utility; Topical treatment; HEALTH STATE UTILITIES; PSORIASIS; MANAGEMENT; PATIENT; BURDEN; ECZEMA; IMPACT; GUIDELINES; PREFERENCE; MODERATE;
D O I
10.1007/s11136-019-02174-0
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Purpose Management of atopic dermatitis (AD) typically requires application of topical treatments, often multiple times a day. The cosmetic properties and burdensome application of these treatments can be detrimental to quality of life (QoL). Patients who achieve good disease control through use of systemic therapies may reduce the frequency and amount of topical applications, improving QoL. This study aimed to quantify the utility and disutility for topical AD treatment processes. Methods Seven vignettes describing different skincare regimens for people with moderate-to-severe AD were developed with input from healthcare professionals. 484 respondents from the general population completed time trade-off items for each vignette. Utility values for each regimen, and disutilities associated with the impact of changes to skincare regimens, were calculated. Analysis of variance assessed differences between skincare regimens. Results As skincare regimens increased in intensity (0.7968 for the most intense; 0.9999 for the least), utility values decreased. There were no statistically significant differences between skincare regimens followed by patients with good disease control (0.9862 to 0.9999); however, when compared to those involving topical corticosteroids and emollient combinations (0.7968 to 0.8835), significant differences were observed (p < 0.001). The largest disutilities (0.1521 to 0.1705) were between skincare regimens describing the use of topical corticosteroids plus emollient and those followed by patients with good disease control. Conclusions The application of topical treatments has a detrimental effect on QoL, which increases with the duration and frequency of applications. Further research is needed to investigate how health and process utilities interact and both can be integrated into medical decision-making.
引用
收藏
页码:2373 / 2381
页数:9
相关论文
共 50 条
  • [1] Process utilities for topical treatment in atopic dermatitis
    Jenny Retzler
    Adam Smith
    Matthew Reaney
    Raj Rout
    Richard Hudson
    Quality of Life Research, 2019, 28 : 2373 - 2381
  • [2] PROCESS UTILITIES FOR TOPICAL TREATMENT IN ATOPIC DERMATITIS
    Retzler, J.
    Smith, A. B.
    Reaney, M.
    Rout, R.
    Hudson, R.
    VALUE IN HEALTH, 2018, 21 : S433 - S433
  • [3] Topical treatment of atopic dermatitis
    Boguniewicz, M
    IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2004, 24 (04) : 631 - +
  • [4] THE EVOLUTION OF TOPICAL TREATMENT OF ATOPIC DERMATITIS
    Wollenberg, Andreas
    ACTA DERMATO-VENEREOLOGICA, 2023, 103 : 10 - 11
  • [5] Topical triclosan treatment of atopic dermatitis
    Sporik, R
    Kemp, AS
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1997, 99 (06) : 861 - 861
  • [6] Topical treatment of atopic dermatitis in infants
    Migacheva, N.
    Kaganova, T.
    Zhestkov, A.
    ALLERGY, 2008, 63 : 328 - 328
  • [7] THE TOPICAL TREATMENT OF THE ATOPIC-DERMATITIS
    MARGHESCU, S
    ALLERGOLOGIE, 1987, 10 (12) : 519 - 522
  • [8] Topical tacrolimus as treatment of atopic dermatitis
    Furue, Masutaka
    Takeuchi, Satoshi
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2009, 2 : 161 - 166
  • [9] Topical tacrolimus for treatment of atopic dermatitis
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2001, 43 (1102): : 33 - 34
  • [10] Topical Treatment for the Management of Atopic Dermatitis
    Hashim, Peter W.
    Chen, Tinley
    Hebert, Adelaide A.
    Kircik, Leon H.
    JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (02) : S112 - S116